Every material Form 8-K KORU Medical Systems, Inc. has filed with the SEC since May 06, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
KORU Medical reported second-quarter 2026 net revenues of $12.0 million, up 18.2%, and net income of $0.25 million, compared with a net loss a year earlier. The company raised its full-year 2026 gross margin guidance and narrowed its revenue guidance, but it also withdrew its U.S. Phesgo 510(k) application and expects international core growth to moderate.
Q2 2026 net revenues were $12.0 million, up from $10.2 million; net income was $0.25 million, or $0.01 per diluted share, versus a net loss of $0.2 million a year earlier.
Gross margin rose to 65.1% from 63.5%; full-year 2026 gross margin guidance was raised to 62% to 64%.
Full-year 2026 revenue guidance was narrowed to $47.5 million to $48.5 million, and year-end cash is now expected to be greater than $7.5 million after a technology acquisition.
The company withdrew its FreedomEDGE with Phesgo 510(k) application in the U.S. and shifted its U.S. oncology strategy to other molecules.
KORU Medical Systems signed Amendment No. 1 to its manufacturing and supply agreement with Command Medical Products on June 24, 2026, covering subassemblies, needle sets and tubing. The amendment extends the initial term to December 31, 2031, makes Command the exclusive manufacturer of a limited set of products, and requires Command to qualify a second manufacturing site by December 31, 2027, with a termination right for KORU if it does not. The filing discloses no financial figures, so its effect on shareholders' results cannot be measured from this document.
Amendment dated June 24, 2026 modifies the January 1, 2024 agreement with Command Medical Products, LLC.
Initial term now expires December 31, 2031, with automatic one-year renewals unless either party gives at least 180 days' notice.
Command must obtain and qualify a second manufacturing site by December 31, 2027; KORU may terminate if Command fails and does not cure within 30 days.
Amendment also changes pricing and payment terms, establishes Command as exclusive manufacturer of a limited set of products, and removes the non-competition provision.
KORU Medical Systems reported first quarter 2026 results, with net revenues up 22.1% to $11.8 million and net loss narrowing to $0.8 million from $1.2 million a year earlier. The company reiterated its full year 2026 guidance of $47.5 million to $50.0 million in net revenues, a gross margin of 61% to 63%, and positive adjusted EBITDA and cash flow.
Q1 2026 net revenues were $11.8 million, up 22.1% from $9.6 million in Q1 2025.
Gross margin fell to 61.5% from 62.8%, which the company attributed to production timing and tariff-related charges.
Net loss was $0.8 million, or $(0.02) per diluted share, compared with $1.2 million, or $(0.03), a year earlier.
Full year 2026 guidance was reiterated, not changed: net revenues of $47.5 million to $50.0 million and cash on hand of $8.8 million at March 31, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every KORU Medical Systems, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →